{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:41:53Z","timestamp":1793324513492,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n              <jats:title>Purpose<\/jats:title>\n              <jats:p>Parathyroid diseases are related to parathyroid hormone (PTH) dysregulation by parathyroid cells or alteration of PTH function. They include hyperparathyroidism (PTH excess), hypoparathyroidism (PTH deficiency) and pseudohypoparathyroidism (PTH resistance). Little is known about correlation between parathyroid diseases and metabolic syndrome (MetS).<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Methods<\/jats:title>\n              <jats:p>An electronic-based search using PubMed was performed until October 2022 and articles were selected based on relevance of title, abstract, English language and publication in peer-reviewed journals.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Results<\/jats:title>\n              <jats:p>Possible association between PTH alterations and the diverse manifestation of MetS have been proposed and it could be supposed that MetS may negatively influence parathyroid diseases. Available data show significant association for hyperparathyroidism and pseudohypoparathyroidism.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Conclusions<\/jats:title>\n              <jats:p>This review highlights the possible implications between MetS and parathyroid diseases. Given the increasing MetS global prevalence and the higher parathyroid diseases awareness and diagnosis, it may be interesting to further explore the possible role of alterations in parathyroid homeostasis in the development of MetS components with dedicated prospective studies.<\/jats:p>\n            <\/jats:sec>","DOI":"10.1007\/s40618-023-02018-2","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T13:35:07Z","timestamp":1676122507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Parathyroid diseases and metabolic syndrome"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3768-5803","authenticated-orcid":false,"given":"R.","family":"Modica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1784-5491","authenticated-orcid":false,"given":"A.","family":"Liccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8823-0702","authenticated-orcid":false,"given":"R.","family":"Minotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4489-3651","authenticated-orcid":false,"given":"E.","family":"Benevento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8524-1131","authenticated-orcid":false,"given":"G.","family":"Cannavale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4049-2559","authenticated-orcid":false,"given":"A.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,11]]},"reference":[{"key":"2018_CR1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","volume":"391","author":"JP Bilezikian","year":"2018","unstructured":"Bilezikian JP, Bandeira L, Khan A et al (2018) Hyperparathyroidism. Lancet 391:168\u2013178","journal-title":"Lancet"},{"key":"2018_CR2","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2015-3908","volume":"101","author":"BL Clarke","year":"2016","unstructured":"Clarke BL, Brown EM, Collins MT et al (2016) Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab 101:2284\u20132299","journal-title":"J Clin Endocrinol Metab"},{"key":"2018_CR3","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","volume":"26","author":"JP Bilezikian","year":"2011","unstructured":"Bilezikian JP, Khan A, Potts JT et al (2011) Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 26:2317\u20132337","journal-title":"J Bone Miner Res"},{"key":"2018_CR4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"D Shoback","year":"2008","unstructured":"Shoback D (2008) Clinical practice. Hypoparathyroidism N Engl J Med 359:391\u2013403","journal-title":"Hypoparathyroidism N Engl J Med"},{"key":"2018_CR5","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s40618-022-01800-y","volume":"45","author":"G Marcucci","year":"2022","unstructured":"Marcucci G, Beccuti G, Carosi G et al (2022) Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1\u201384) treatment. J Endocrinol Invest 45:1653\u20131662","journal-title":"J Endocrinol Invest"},{"key":"2018_CR6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00223-018-0411-7","volume":"103","author":"G Marcucci","year":"2018","unstructured":"Marcucci G, Cianferotti L, Parri S et al (2018) HypoparaNet: a database of chronic hypoparathyroidism based on expert medical-surgical centers in Italy. Calcif Tissue Int 103:151\u2013163","journal-title":"Calcif Tissue Int"},{"key":"2018_CR7","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/cen.12948","volume":"84","author":"L Underbjerg","year":"2016","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L et al (2016) Pseudohypoparathyroidism - epidemiology, mortality and risk of complications. Clin Endocrinol (Oxf) 84:904\u2013911","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2018_CR8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jocd.2012.11.012","volume":"16","author":"SA Jamal","year":"2013","unstructured":"Jamal SA, Miller PD (2013) Secondary and tertiary hyperparathyroidism. J Clin Densitom 16:64\u201368","journal-title":"J Clin Densitom"},{"key":"2018_CR9","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/joim.12523","volume":"280","author":"RV Thakker","year":"2016","unstructured":"Thakker RV (2016) Genetics of parathyroid tumours. J Intern Med 280:574\u2013583","journal-title":"J Intern Med"},{"key":"2018_CR10","first-page":"65","volume":"63","author":"M Bastepe","year":"2005","unstructured":"Bastepe M, J\u00fcppner H (2005) GNAS locus and pseudohypoparathyroidism. Horm Res 63:65\u201374","journal-title":"Horm Res"},{"key":"2018_CR11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","volume":"20","author":"MG Saklayen","year":"2018","unstructured":"Saklayen MG (2018) The global epidemic of the metabolic syndrome. Curr Hypertens Rep 20:12","journal-title":"Curr Hypertens Rep"},{"key":"2018_CR12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.ijo.0803797","volume":"32","author":"W Gao","year":"2008","unstructured":"Gao W, DECODE Study Group (2008) Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk? Int J Obes (Lond) 32:757\u2013762","journal-title":"Int J Obes (Lond)"},{"key":"2018_CR13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","volume":"366","author":"KGMM Alberti","year":"2005","unstructured":"Alberti KGMM, Zimmet P, Shaw J et al (2005) The metabolic syndrome\u2013a new worldwide definition. Lancet 366:1059\u20131062","journal-title":"Lancet"},{"key":"2018_CR14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/a-1263-0898","volume":"42","author":"A Bovolini","year":"2021","unstructured":"Bovolini A, Garcia J, Andrade MA et al (2021) Metabolic syndrome pathophysiology and predisposing factors. Int J Sports Med 42:199\u2013214","journal-title":"Int J Sports Med"},{"key":"2018_CR15","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s40618-022-01818-2","volume":"45","author":"S Saha","year":"2022","unstructured":"Saha S, Mannar V, Kandasamy D et al (2022) Vertebral fractures, trabecular bone score and their determinants in chronic hypoparathyroidism. J Endocrinol Invest 45:1777\u20131786","journal-title":"J Endocrinol Invest"},{"key":"2018_CR16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0306-9877(03)00227-5","volume":"61","author":"MF McCarty","year":"2003","unstructured":"McCarty MF, Thomas CA (2003) PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses 61:535\u2013542","journal-title":"Med Hypotheses"},{"key":"2018_CR17","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1210\/jc.2004-1891","volume":"90","author":"MJ Bolland","year":"2005","unstructured":"Bolland MJ, Grey AB, Gamble GD et al (2005) Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab 90:1525\u20131530","journal-title":"J Clin Endocrinol Metab"},{"key":"2018_CR18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/cvr\/cvs092","volume":"94","author":"A Tomaschitz","year":"2012","unstructured":"Tomaschitz A, Ritz E, Pieske B et al (2012) Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res 94:10\u201319","journal-title":"Cardiovasc Res"},{"key":"2018_CR19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105129","volume":"89","author":"C Cormier","year":"2022","unstructured":"Cormier C, Koumakis E (2022) Bone and primary hyperparathyroidism. Joint Bone Spine 89:105129","journal-title":"Joint Bone Spine"},{"key":"2018_CR20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1067\/msy.2001.118377","volume":"130","author":"E Lundgren","year":"2001","unstructured":"Lundgren E, Lind L, Palm\u00e9r M et al (2001) Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery 130:978\u2013985","journal-title":"Surgery"},{"key":"2018_CR21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.numecd.2020.12.029","volume":"31","author":"S Frey","year":"2021","unstructured":"Frey S, Miralli\u00e9 \u00c9, Cariou B et al (2021) Impact of parathyroidectomy on cardiovascular risk in primary hyperparathyroidism: a narrative review. Nutr Metab Cardiovasc Dis 31:981\u2013996","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2018_CR22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40618-021-01645-x","volume":"45","author":"S Purra","year":"2022","unstructured":"Purra S, Lone AA, Bhat MH et al (2022) Cardiac structural and functional abnormalities in primary hyperparathyroidism. J Endocrinol Invest 45:327\u2013335","journal-title":"J Endocrinol Invest"},{"key":"2018_CR23","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1210\/jc.2013-3903","volume":"99","author":"H Tran","year":"2014","unstructured":"Tran H, Grange JS, Adams-Huet B et al (2014) The impact of obesity on the presentation of primary hyperparathyroidism. J Clin Endocrinol Metab 99:2359\u20132364","journal-title":"J Clin Endocrinol Metab"},{"key":"2018_CR24","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s12020-021-02635-y","volume":"72","author":"T-J Yuan","year":"2021","unstructured":"Yuan T-J, Chen L-P, Pan Y-L et al (2021) An inverted U-shaped relationship between parathyroid hormone and body weight, body mass index, body fat. Endocrine 72:844\u2013851","journal-title":"Endocrine"},{"key":"2018_CR25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature13528","volume":"513","author":"S Kir","year":"2014","unstructured":"Kir S, White JP, Kleiner S et al (2014) Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 513:100\u2013104","journal-title":"Nature"},{"key":"2018_CR26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/dmrr.637","volume":"23","author":"AA Khaleeli","year":"2007","unstructured":"Khaleeli AA, Johnson JN, Taylor WH (2007) Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy. Diabetes Metab Res Rev 23:43\u201348","journal-title":"Diabetes Metab Res Rev"},{"key":"2018_CR27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2265.1994.tb02442.x","volume":"40","author":"S Kumar","year":"1994","unstructured":"Kumar S, Olukoga AO, Gordon C et al (1994) Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin Endocrinol (Oxf) 40:47\u201353","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2018_CR28","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1046\/j.1464-5491.2002.00809.x","volume":"19","author":"M Procopio","year":"2002","unstructured":"Procopio M, Magro G, Cesario F et al (2002) The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 19:958\u2013961","journal-title":"Diabet Med"},{"key":"2018_CR29","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1210\/jc.2018-02456","volume":"104","author":"H Ejlsmark-Svensson","year":"2019","unstructured":"Ejlsmark-Svensson H, Rolighed L, Rejnmark L (2019) Effect of parathyroidectomy on cardiovascular risk factors in primary hyperparathyroidism: a randomized clinical trial. J Clin Endocrinol Metab 104:3223\u20133232","journal-title":"J Clin Endocrinol Metab"},{"key":"2018_CR30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1530\/EJE-13-0547","volume":"169","author":"S Norenstedt","year":"2013","unstructured":"Norenstedt S, Pernow Y, Brismar K et al (2013) Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study. Eur J Endocrinol 169:795\u2013804","journal-title":"Eur J Endocrinol"},{"key":"2018_CR31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.0300-0664.2001.01468.x","volume":"56","author":"E Hagstr\u00f6m","year":"2002","unstructured":"Hagstr\u00f6m E, Lundgren E, Lithell H et al (2002) Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin Endocrinol (Oxf) 56:253\u2013260","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2018_CR32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijcard.2016.11.080","volume":"227","author":"A Kalla","year":"2017","unstructured":"Kalla A, Krishnamoorthy P, Gopalakrishnan A et al (2017) Primary hyperparathyroidism predicts hypertension: results from the national inpatient sample. Int J Cardiol 227:335\u2013337","journal-title":"Int J Cardiol"},{"key":"2018_CR33","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.surg.2009.09.024","volume":"146","author":"A Heyliger","year":"2009","unstructured":"Heyliger A, Tangpricha V, Weber C et al (2009) Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism. Surgery 146:1042\u20131047","journal-title":"Surgery"},{"key":"2018_CR34","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/309068","volume":"2011","author":"PD Broulik","year":"2011","unstructured":"Broulik PD, Broulikov\u00e1 A, Ad\u00e1mek S et al (2011) Improvement of hypertension after parathyroidectomy of patients suffering from primary hyperparathyroidism. Int J Endocrinol 2011:309068","journal-title":"Int J Endocrinol"},{"key":"2018_CR35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamasurg.2019.3950","volume":"155","author":"AN Graff-Baker","year":"2020","unstructured":"Graff-Baker AN, Bridges LT, Chen Q et al (2020) Parathyroidectomy for patients with primary hyperparathyroidism and associations with hypertension. JAMA Surg 155:32\u201339","journal-title":"JAMA Surg"},{"key":"2018_CR36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.trsl.2016.12.004","volume":"183","author":"X Zhang","year":"2017","unstructured":"Zhang X, Lerman LO (2017) The metabolic syndrome and chronic kidney disease. Transl Res 183:14\u201325","journal-title":"Transl Res"},{"key":"2018_CR37","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2215\/CJN.07730814","volume":"10","author":"PS Parfrey","year":"2015","unstructured":"Parfrey PS, Dr\u00fceke TB, Block GA et al (2015) the effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol 10:791\u2013799","journal-title":"Clin J Am Soc Nephrol"},{"key":"2018_CR38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.23736\/S2724-6507.20.03299-X","volume":"46","author":"L Barrea","year":"2021","unstructured":"Barrea L, Frias-Toral E, Pugliese G et al (2021) Vitamin D in obesity and obesity-related diseases: an overview. Minerva endocrinology 46:177\u2013192","journal-title":"Minerva endocrinology"},{"key":"2018_CR39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40618-021-01633-1","volume":"45","author":"L Meng","year":"2022","unstructured":"Meng L, Su C, Shapses SA et al (2022) Total and free vitamin D metabolites in patients with primary hyperparathyroidism. J Endocrinol Invest 45:301\u2013307","journal-title":"J Endocrinol Invest"},{"key":"2018_CR40","first-page":"453","volume":"46","author":"V Kamwa","year":"2021","unstructured":"Kamwa V, Welch C, Hassan-Smith ZK (2021) The endocrinology of sarcopenia and frailty. Minerva endocrinology 46:453\u2013468","journal-title":"Minerva endocrinology"},{"key":"2018_CR41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/obr.12239","volume":"16","author":"M Pereira-Santos","year":"2015","unstructured":"Pereira-Santos M, Costa PRF, Assis AMO et al (2015) Obesity and vitamin D deficiency: a systematic review and meta-analysis. Obes Rev 16:341\u2013349","journal-title":"Obes Rev"},{"key":"2018_CR42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1470320310391922","volume":"12","author":"A Vaidya","year":"2011","unstructured":"Vaidya A, Forman JP, Hopkins PN et al (2011) 25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst 12:311\u2013319","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2018_CR43","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/jhh.2010.110","volume":"25","author":"A Vaidya","year":"2011","unstructured":"Vaidya A, Forman JP, Williams JS (2011) Vitamin D and the vascular sensitivity to angiotensin II in obese Caucasians with hypertension. J Hum Hypertens 25:672\u2013678","journal-title":"J Hum Hypertens"},{"key":"2018_CR44","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1161\/HYPERTENSIONAHA.109.148619","volume":"55","author":"JP Forman","year":"2010","unstructured":"Forman JP, Williams JS, Fisher NDL (2010) Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 55:1283\u20131288","journal-title":"Hypertension"},{"key":"2018_CR45","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/HJH.0000000000001220","volume":"35","author":"CJ McMullan","year":"2017","unstructured":"McMullan CJ, Borgi L, Curhan GC et al (2017) The effect of vitamin D on renin-angiotensin system activation and blood pressure: a randomized control trial. J Hypertens 35:822\u2013829","journal-title":"J Hypertens"},{"key":"2018_CR46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jsbmb.2015.12.001","volume":"164","author":"J el Hilali","year":"2016","unstructured":"el Hilali J, de Koning EJ, van Ballegooijen AJ et al (2016) Vitamin D, PTH and the risk of overall and disease-specific mortality: results of the longitudinal aging study Amsterdam. J Steroid Biochem Mol Biol 164:386\u2013394","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2018_CR47","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1210\/jc.2015-1477","volume":"100","author":"T Harsl\u00f8f","year":"2015","unstructured":"Harsl\u00f8f T, Sikj\u00e6r T, S\u00f8rensen L et al (2015) The effect of treatment with PTH on undercarboxylated osteocalcin and energy metabolism in hypoparathyroidism. J Clin Endocrinol Metab 100:2758\u20132762","journal-title":"J Clin Endocrinol Metab"},{"key":"2018_CR48","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/jbmr.1964","volume":"28","author":"T Sikjaer","year":"2013","unstructured":"Sikjaer T, Amstrup AK, Rolighed L et al (2013) PTH(1\u201384) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. J Bone Miner Res 28:2232\u20132243","journal-title":"J Bone Miner Res"},{"key":"2018_CR49","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/ijo.2012.169","volume":"37","author":"M Valette","year":"2013","unstructured":"Valette M, Bellisle F, Carette C et al (2013) Eating behaviour in obese patients with melanocortin-4 receptor mutations: a literature review. Int J Obes (Lond) 37:1027\u20131035","journal-title":"Int J Obes (Lond)"},{"key":"2018_CR50","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMoa022050","volume":"348","author":"IS Farooqi","year":"2003","unstructured":"Farooqi IS, Keogh JM, Yeo GSH et al (2003) Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348:1085\u20131095","journal-title":"N Engl J Med"},{"key":"2018_CR51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1687-9856-2014-21","volume":"2014","author":"L Wang","year":"2014","unstructured":"Wang L, Shoemaker AH (2014) Eating behaviors in obese children with pseudohypoparathyroidism type 1a: a cross-sectional study. Int J Pediatr Endocrinol 2014:21","journal-title":"Int J Pediatr Endocrinol"},{"key":"2018_CR52","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1210\/jc.2006-1497","volume":"92","author":"DN Long","year":"2007","unstructured":"Long DN, McGuire S, Levine MA et al (2007) Body mass index differences in pseudohypoparathyroidism type 1a versus pseudopseudohypoparathyroidism may implicate paternal imprinting of Galpha(s) in the development of human obesity. J Clin Endocrinol Metab 92:1073\u20131079","journal-title":"J Clin Endocrinol Metab"},{"key":"2018_CR53","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/oby.2007.216","volume":"15","author":"EM Dykens","year":"2007","unstructured":"Dykens EM, Maxwell MA, Pantino E et al (2007) Assessment of hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring) 15:1816\u20131826","journal-title":"Obesity (Silver Spring)"},{"key":"2018_CR54","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/1469-7610.00792","volume":"42","author":"J Wardle","year":"2001","unstructured":"Wardle J, Guthrie CA, Sanderson S et al (2001) Development of the children\u2019s eating behaviour questionnaire. J Child Psychol Psychiatry 42:963\u2013970","journal-title":"J Child Psychol Psychiatry"},{"key":"2018_CR55","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1210\/jc.2015-3895","volume":"101","author":"JD Roizen","year":"2016","unstructured":"Roizen JD, Danzig J, Groleau V et al (2016) Resting energy expenditure is decreased in pseudohypoparathyroidism Type 1A. J Clin Endocrinol Metab 101:880\u2013888","journal-title":"J Clin Endocrinol Metab"},{"key":"2018_CR56","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrendo.2009.81","volume":"5","author":"BU Nwosu","year":"2009","unstructured":"Nwosu BU, Lee MM (2009) Pseudohypoparathyroidism type 1a and insulin resistance in a child. Nat Rev Endocrinol 5:345\u2013350","journal-title":"Nat Rev Endocrinol"},{"key":"2018_CR57","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1210\/jc.2003-030028","volume":"88","author":"EL Germain-Lee","year":"2003","unstructured":"Germain-Lee EL, Groman J, Crane JL et al (2003) Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. J Clin Endocrinol Metab 88:4059\u20134069","journal-title":"J Clin Endocrinol Metab"},{"key":"2018_CR58","doi-asserted-by":"crossref","first-page":"E1796","DOI":"10.1210\/jc.2013-1594","volume":"98","author":"R Muniyappa","year":"2013","unstructured":"Muniyappa R, Warren MA, Zhao X et al (2013) Reduced insulin sensitivity in adults with pseudohypoparathyroidism type 1a. J Clin Endocrinol Metab 98:E1796\u2013E1801","journal-title":"J Clin Endocrinol Metab"},{"key":"2018_CR59","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1677\/JOE-10-0030","volume":"206","author":"T Xie","year":"2010","unstructured":"Xie T, Chen M, Weinstein LS (2010) Pancreas-specific Gsalpha deficiency has divergent effects on pancreatic alpha- and beta-cell proliferation. J Endocrinol 206:261\u2013269","journal-title":"J Endocrinol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02018-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02018-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02018-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T12:26:23Z","timestamp":1725539183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02018-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,11]]},"references-count":59,"alternative-id":["2018"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02018-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,11]]},"assertion":[{"value":"20 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}